Immunotherapy, which harnesses the body's own immune system to combat cancer, has emerged as a major therapeutic modality across many oncology fields, and the soft tissue sarcoma (STS) market is no exception. While STS was initially considered relatively "cold" (less responsive) to single-agent immune checkpoint inhibitors compared to other solid tumors, recent clinical research has...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)